•  
  •  
  •  
  •  

2025-10-21 01:00:50

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Marathon Nextgen Realty announces one of the Largest Commercial Projects in Mumbai in JV with Adani Realty
  • Geojit Financial Services Ltd consolidated Q2FY26 PAT falls to Rs. 22.37 crores
  • VMS TMT bags more than 10,000 Metric Ton Order from Distributor Network amounting to approx. ₹ 46 Crores
  • AB Cotspin announces Order worth around ₹5.45 Crore for 200 MT of Cotton Yarn
  • Unimech Aerospace commissions two new manufacturing facilities at Bengaluru, KIADB Park

Keywords Selected:  BioconBiologics

Stock Report

  • Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine
  • Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
  • U.S. FDA Completes Inspection at Biocon Biologics' Facility at Biocon Campus, Bengaluru, India
  • Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™
  • Biocon Biologics receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars
  • Biocon Biologics expands Insulin Access in Malaysia
  • Biocon Biologics receives Health Canada approval for Yesafili™
  • Biocon Biologics Collaborates with National Cancer Society Malaysia
  • Biocon Biologics and Yoshindo expand access to Ustekinumab Biosimilar in Japan
  • Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives
  • Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe
  • Biocon Biologics secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
  • Biocon Biologics announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
  • Biocon Biologics and Civica, Inc. collaborate to expand Insulin Aspart access in the United States
  • Biocon Biologics Launches Yesintekâ„¢ Biosimilar to Stelara® in the United States
  • European Commission approves Biocon Biologics' Ustekinumab Biosimilar
  • EMA's CHMP recommends approval of Biocon Biologics' YESINTEK®, biosimilar to J&J's Stelara®
  • Biocon Biologics Recognized as Asia IP Elite for 2024 by IAM, Cementing Leadership in Intellectual Property Excellence
  • U.S.FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 biosimilar to J&J's Stelara® (Ustekinumab)
  • Biocon Biologics Refinances USD 1.1 Billion Long Term Debt through USD Bonds and New Syndicated Facility
  • Biocon Biologics announces New Dermatology Data to be presented at EADV Congress 2024
  • Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan
  • EMA Approves Biocon Biologics' New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites
  • Eris Lifesciences acquires the commercial rights to Biocon Biologics' India Branded Formulations business

Latest Post

  • Marathon Nextgen Realty announces one of the Largest Commercial Projects in Mumbai in JV with Adani Realty
  • Geojit Financial Services Ltd consolidated Q2FY26 PAT falls to Rs. 22.37 crores
  • VMS TMT bags more than 10,000 Metric Ton Order from Distributor Network amounting to approx. ₹ 46 Crores
  • AB Cotspin announces Order worth around ₹5.45 Crore for 200 MT of Cotton Yarn
  • Unimech Aerospace commissions two new manufacturing facilities at Bengaluru, KIADB Park


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024